Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Depreciation & Amortization (CF) (2019 - 2025)

VYNE Therapeutics' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $6000.0 for Q2 2025.

  • For Q2 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $6000.0; the TTM value through Dec 2025 reached $12000.0, changed N/A, while the annual FY2025 figure was $23000.0, 475.0% up from the prior year.
  • Depreciation & Amortization (CF) reached $6000.0 in Q2 2025 per VYNE's latest filing, roughly flat from $6000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $171000.0 in Q3 2022 to a low of -$155000.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 3 years is $19300.0, with a median of $26500.0 recorded in 2021.
  • The largest YoY upside for Depreciation & Amortization (CF) was 510.71% in 2022 against a maximum downside of 696.15% in 2022.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $26000.0 in 2021, then plummeted by 696.15% to -$155000.0 in 2022, then surged by 103.87% to $6000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Depreciation & Amortization (CF) are $6000.0 (Q2 2025), $6000.0 (Q1 2025), and -$155000.0 (Q4 2022).